Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 427 entries
View as:

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01478685 Org: User:
Start: 11/29/11 End: 11/17/15 Due: 11/17/16

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT02509039 Org: User:
Start: 09/02/15 End: 05/09/23 Due: 05/09/24

Treatment of Pancreatic Cancer With Abraxane

Phase: N/A Priority: Normal
NCT ID: NCT02555813 Org: User:
Start: 05/08/15 End: 09/07/20 Due: 09/07/21

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03824678 Org: User:
Start: 02/13/19 End: 06/18/19 Due: 06/18/20

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase: N/A Priority: Normal
NCT ID: NCT03374085 Org: User:
Start: 02/06/18 End: 01/31/28 Due: 01/31/29

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Phase: N/A Priority: Normal
NCT ID: NCT01712828 Org: User:
Start: 10/01/12 End: 01/01/13 Due: 01/01/14

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00458159 Org: User:
Start: 05/01/07 End: 12/01/08 Due: 12/01/09

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02546986 Org: User:
Start: 10/09/15 End: 06/30/25 Due: 06/30/26

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02103335 Org: User:
Start: 06/05/14 End: 11/30/16 Due: 11/30/17

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02677922 Org: User:
Start: 06/03/16 End: 09/30/25 Due: 09/30/26

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Phase: N/A Priority: Normal
NCT ID: NCT03194542 Org: User:
Start: 11/15/17 End: 07/18/22 Due: 07/18/23

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01734928 Org: User:
Start: 01/07/13 End: 05/13/22 Due: 05/13/23

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT01203943 Org: User:
Start: 01/01/11 End: 08/24/12 Due: 08/24/13

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase: N/A Priority: Normal
NCT ID: NCT04975997 Org: User:
Start: 06/23/22 End: 06/25/32 Due: 06/25/33

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03220347 Org: User:
Start: 07/24/17 End: 09/06/24 Due: 09/06/25

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Phase: N/A Priority: Normal
NCT ID: NCT02741544 Org: User:
Start: 03/03/16 End: 08/20/20 Due: 08/20/21

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02596893 Org: User:
Start: 12/08/15 End: 01/05/18 Due: 01/05/19

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03310619 Org: User:
Start: 12/20/17 End: 02/15/23 Due: 02/15/24

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Phase: N/A Priority: Normal
NCT ID: NCT02164955 Org: User:
Start: 06/26/14 End: 10/10/22 Due: 10/10/23

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01632826 Org: User:
Start: - End: - Due: -

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00547651 Org: User:
Start: 09/01/07 End: 05/01/11 Due: 05/01/12

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02285062 Org: User:
Start: 02/17/15 End: 07/28/22 Due: 07/28/23

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

Phase: N/A Priority: Normal
NCT ID: NCT03624959 Org: User:
Start: 06/20/18 End: 08/10/18 Due: 08/10/19

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04884035 Org: User:
Start: 09/15/21 End: 06/21/27 Due: 06/21/28

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04748848 Org: User:
Start: 10/14/21 End: 03/09/22 Due: 03/09/23